Squarepoint’s Regenxbio RGNX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $142K | Sell |
16,981
-25,937
| -60% | -$272K | ﹤0.01% | 4021 |
|
|
2025
Q4 | $618K | Sell |
42,918
-163,489
| -79% | -$2.04M | ﹤0.01% | 3038 |
|
|
2025
Q3 | $1.99M | Sell |
206,407
-12,881
| -6% | -$114K | ﹤0.01% | 2111 |
|
|
2025
Q2 | $1.8M | Buy |
219,288
+209,084
| +2,049% | +$1.75M | ﹤0.01% | 2181 |
|
|
2025
Q1 | $73K | Sell |
10,204
-27,026
| -73% | -$201K | ﹤0.01% | 4289 |
|
|
2024
Q4 | $288K | Sell |
37,230
-2,475
| -6% | -$23.2K | ﹤0.01% | 4179 |
|
|
2024
Q3 | $417K | Sell |
39,705
-106,554
| -73% | -$1.3M | ﹤0.01% | 3236 |
|
|
2024
Q2 | $1.71M | Buy |
146,259
+126,249
| +631% | +$1.97M | ﹤0.01% | 2163 |
|
|
2024
Q1 | $422K | Buy |
+20,010
| New | +$356K | ﹤0.01% | 3169 |
|
|
2023
Q4 | – | Sell |
-41,592
| Closed | -$685K | – | 4412 |
|
|
2023
Q3 | $685K | Buy |
+41,592
| New | +$754K | ﹤0.01% | 2567 |
|
|
2021
Q4 | – | Sell |
-47,605
| Closed | -$2M | – | 3464 |
|
|
2021
Q3 | $2M | Buy |
47,605
+20,463
| +75% | +$736K | 0.01% | 1202 |
|
|
2021
Q2 | $1.05M | Buy |
27,142
+4,776
| +21% | +$171K | ﹤0.01% | 1591 |
|
|
2021
Q1 | $763K | Buy |
22,366
+5,127
| +30% | +$219K | ﹤0.01% | 1722 |
|
|
2020
Q4 | $782K | Sell |
17,239
-28,342
| -62% | -$990K | 0.01% | 1484 |
|
|
2020
Q3 | $1.25M | Buy |
45,581
+21,425
| +89% | +$698K | 0.02% | 870 |
|
|
2020
Q2 | $890K | Buy |
24,156
+14,660
| +154% | +$547K | 0.01% | 1009 |
|
|
2020
Q1 | $307K | Sell |
9,496
-33,484
| -78% | -$1.4M | 0.01% | 1290 |
|
|
2019
Q4 | $1.76M | Buy |
42,980
+8,055
| +23% | +$318K | 0.01% | 985 |
|
|
2019
Q3 | $1.24M | Buy |
+34,925
| New | +$1.42M | 0.01% | 1080 |
|
|
2019
Q2 | – | Sell |
-60,537
| Closed | -$3.47M | – | 2629 |
|
|
2019
Q1 | $3.47M | Buy |
60,537
+32,192
| +114% | +$1.59M | 0.04% | 566 |
|
|
2018
Q4 | $1.19M | Buy |
+28,345
| New | +$1.66M | 0.01% | 853 |
|
|
2018
Q3 | – | Sell |
-6,725
| Closed | -$483K | – | 2179 |
|
|
2018
Q2 | $483K | Sell |
6,725
-19,384
| -74% | -$926K | 0.01% | 1206 |
|
|
2018
Q1 | $779K | Sell |
26,109
-9,312
| -26% | -$271K | 0.01% | 903 |
|
|
2017
Q4 | $1.18M | Buy |
+35,421
| New | +$1.07M | 0.02% | 758 |
|
|
2017
Q1 | – | Sell |
-12,038
| Closed | -$223K | – | 1854 |
|
|
2016
Q4 | $223K | Buy |
+12,038
| New | +$230K | 0.01% | 1360 |
|
Other funds holding RGNX
RG
VCM
IHAM
Squarepoint's RGNX Position: Q1 2026 in Review
Squarepoint reduced its Regenxbio (RGNX) stake by 60% in Q1 2026, selling an estimated $272K and leaving 16,981 shares worth $142K. The position accounts for ﹤0.01% of the portfolio, ranked #4021.
Squarepoint first reported a position in RGNX in Q4 2016 and has held it in 25 quarters since. The position peaked at $3.47M in Q1 2019. 178 funds tracked by Wall St. Rank hold RGNX as of Q1 2026.
- Squarepoint held 16,981 shares of Regenxbio worth $142K as of Q1 2026.
- Squarepoint sold 25,937 Regenxbio shares in Q1 2026, an estimated $272K.
- Regenxbio made up ﹤0.01% of Squarepoint's portfolio in Q1 2026, its #4021 holding.
- Squarepoint first reported a position in Regenxbio in Q4 2016 and has held it in 25 quarters since.
- Squarepoint's Regenxbio position peaked at $3.47M in Q1 2019.
- 178 funds tracked by Wall St. Rank held Regenxbio as of Q1 2026.
Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.